drugset / Trial / NCT03938987
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Phase 1/2
Recruiting
63 enrolled
University of Alberta
Alberta Cancer Foundation · collabCanadian Cancer Trials Group · collab
NaSingle-groupOpen-labelTreatment
Summary
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).
Timeline
- Start
- 2021-03-03
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 1 cells/kg | Intravenous |
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 2 cells/kg | Intravenous |